Nasal COVID-19 vaccine to enter US clinical trials
A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...
Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018
Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...